Clinical Trials Logo

Head and Neck Neoplasms clinical trials

View clinical trials related to Head and Neck Neoplasms.

Filter by:

NCT ID: NCT05200650 Not yet recruiting - Clinical trials for Head and Neck Cancer

A Single Arm, Prospective, Open Label, Multi Center, Phase Ib Study to Evaluate the Safety, Tolerability and Initial Efficacy of a Single Intra-tumoral Injection of IntraGel's Polymer-based Cisplatin-loaded Gel (TumoCure) in Subjects With Progressive or Radio-resistant Primary Head and Neck Tumor

Start date: March 15, 2022
Phase: Phase 1
Study type: Interventional

IntraGel's polymer-based Cisplatin loaded Gel (TumoCure) is a single injectable compound, aimed at localized chemotherapy treatment. The treatment is offered to patients who currently have no other available treatment options, either due to inefficacy, intolerability or inapplicability of standard treatment

NCT ID: NCT05196087 Not yet recruiting - Breast Cancer Clinical Trials

Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)

NIP IT!
Start date: January 2022
Phase:
Study type: Observational

Patients who have undergone curative treatment may be at risk of relapse. This study will collect, annotate, and sequence biospecimens (blood, stool, and tissue) from patients across different tumor types to detect molecular residual disease (MRD) before metastases become radiographically or clinically detectable. This will allow for early cancer interception, and hopefully prolong relapse-free survival across tumor types.

NCT ID: NCT05187091 Recruiting - Clinical trials for Head and Neck Neoplasms

The SWOAR Trial Swallowing and Aspiration Related Organs at Risk & Submandibular Gland With Intensity Modulated Radiotherapy Versus Standard IMRT in Head and Neck Squamous Cell Carcinomas

SWOAR
Start date: July 11, 2021
Phase: Phase 3
Study type: Interventional

The aim of this study is to test the potential of IMRT in sparing of Dysphagia/ Aspiration risk structures and contra lateral submandibular gland in HNSCC of the oropharynx, larynx and the hypopharynx after radical concurrent chemoradiotherapy or radiotherapy. Primary objective of the SWOAR trial is to determine whether sparing the dysphagia aspiration-related structures (DARS) by IMRT (SWOAR IMRT) improves swallowing function compared to Standar IMRT (S- IMRT) in advanced HNSCC. The impact of sparing the DARS with SWOAR-IMRT on late swallowing function will be evaluated the MDADI. Difference in the mean composite score of MDADI, a patient-reported outcome, at 6 months post radiotherapy is the primary outcome of the trial. Secondary Objectives include longitudinal assessment of aspiration prevention as evaluated by FEES by the 8 point penetration-aspiration score. Swallowing function, will be assessed by using the MDADI at baseline, at completion of CRT/RT, 3, 6, 12, and 24 months. Assessment of acute and late toxicity assessed at baseline, weekly during radiotherapy and then at 3, 6, 12, and 24 months post treatment as per RTOG and LENT SOMA score, respectively. Treatment outcomes will be assessed in terms of loco-regional tumor recurrence and overall survival, assessed at follow-up visits 3, 6, 12, and 24 months post treatment and then annually until 5 years post treatment.

NCT ID: NCT05183243 Not yet recruiting - Colorectal Cancer Clinical Trials

Dose Finding Study of GH21 in Adult Patients With Advanced Solid Tumors

Start date: February 20, 2022
Phase: Phase 1
Study type: Interventional

Evaluate the safety and tolerability of GH21 in patients with advanced solid tumors. Estimate the maximum tolerated dose (MTD) in patients with advanced solid tumors.

NCT ID: NCT05182866 Not yet recruiting - Clinical trials for Head and Neck Cancer

ASP-1929 Photoimmunotherapy (PIT) Study in in Patients With Recurrent Head/Neck Cancer

Start date: January 10, 2022
Phase: Phase 2
Study type: Interventional

A Phase 1/2, Open-label, Single-arm, Window of opportunity Study of ASP-1929 Photoimmunotherapy with Fluorescence Imaging in Patients with Operable Primary or Recurrent Head and Neck or Cutaneous Squamous Cell Carcinoma

NCT ID: NCT05182229 Not yet recruiting - Clinical trials for Head and Neck Cancer

Comparing Two Ways to Manage Head and Neck Lymphedema

Start date: December 31, 2021
Phase: N/A
Study type: Interventional

This randomized clinical trial aims to compare therapist-administered (usual care, clinic-based) CDT and self-administered (home-based, hybrid model) CDT on changes in the severity of lymphedema, symptom burden, functional status, and healthcare utilization in HNC survivors with lymphedema.

NCT ID: NCT05179824 Recruiting - Breast Cancer Clinical Trials

Tempus Priority Study: A Pan-tumor Observational Study

Start date: October 19, 2020
Phase:
Study type: Observational

Observational study that will be collecting clinical and molecular health information from cancer patients who have received comprehensive genomic profiling and meet the specific eligibility criteria outlined for each cohort with the goal of conducting research to advance cancer care and create a dataset that furthers cancer research.

NCT ID: NCT05172258 Not yet recruiting - Clinical trials for Head and Neck Squamous Cell Carcinoma

Pembrolizumab Alone or in Combination With Ipatasertib for the Treatment of Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

Start date: January 22, 2022
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well pembrolizumab alone or in combination with ipatasertib works in treating patients with squamous cell cancer of the head and neck that has come back (recurrent) or has spread to other places in the body (metastatic). Ipatasertib is an orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving ipatasertib in combination with pembrolizumab may kill more tumor cells in patients with recurrent/metastatic squamous cell cancer of the head and neck.

NCT ID: NCT05172245 Not yet recruiting - Clinical trials for Locally Advanced Head and Neck Squamous Cell Carcinoma

Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Stage III-IVB Head and Neck Cancer

Start date: January 14, 2022
Phase: Phase 1
Study type: Interventional

This phase I/Ib trial tests the safety and best dose of ipatasertib in combination with the usual treatment approach chemotherapy given together with radiation therapy ("chemo-radiation") that can be safely and tolerably taken by patients with stage III-IVB head and neck cancer. AKT inhibitors such as, ipatasertib work to stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy to kill tumor cells and shrink tumors. Giving ipatasertib with chemoradiation may help cure head and neck cancer.

NCT ID: NCT05169437 Not yet recruiting - Pancreatic Cancer Clinical Trials

Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors

Start date: January 1, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to further evaluate the efficacy and safety of niraparib in patients with locally advanced or metastatic solid tumors and a pathogenic or likely pathogenic tumor PALB2 (tPALB2) mutation.